Eisai Plans $105-Million Pharma Production and Formulation R&D Facility

March 9, 2006
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Eisai Plans $105 Million Pharma Production and Formulation R&D Facility

Eisai Inc. (Teaneck, NJ, www.eiasi.com), the US pharmaceutical subsidiary of Eisai Co. Ltd. (Tokyo, Japan, www.eisai.co.jp), plans to invest $105 million for a new pharmaceutical production and formulation R&D facility for parenteral oncology treatments in Research Triangle Park, North Carolina.

Of the $105-million capital project, $90 million will be used to build a roughly 65,000-square foot facility that will encompass aseptic processing suites, laboratories, and other support functions. The remaining $15 million will be used to construct a separate central utilities building to supply power, steam, chilled water, and compressed air to existing operations and the new parenteral facility.

Eisai’s existing facility at Research Triangle Park encompasses roughly 190,000 square feet. It is used for the manufacture of  “Aricpet” (donepezil) and “Aciphex” (rabeprazole), formulation R&D, and manufacturing of compounds for use in clinical trials.  

Groundbreaking for the project is expected in the fall, and operations are expected to begin in 2009.

Related Content:

PharmTech News